Glaxosmithkline Research & Development Limited — Sponsor Intelligence | 85 EU Trials

Filter these 85 trials by condition, phase, country and more.

Open in Search →

85 Registered trials

24 Recruiting

55 Completed trials

23 Countries active

60 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 23 Phase II/III: 2 Phase II: 26 Phase I/II: 6 Phase IV: 2 Phase I: 6 Phase I (Other): 13 Phase I (FiH): 7

Oversight events:

5 temporary halts 1 urgent safety measure 3 corrective measures across 5 trials

View oversight register →

100%

55 of 55 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Systemic lupus erythematosus 4 Non-small cell lung cancer 3 Asthma 3 Chronic hepatitis B 3 Hypereosinophilic syndrome 2 Squamous cell carcinoma of head and neck 2 Eosinophilic granulomatosis with polyangiitis 1 Myelofibrosis 1 Osteoarthritis 1 Primary myelofibrosis 1 Adenocarcinoma of colon 1 Cholestatic pruritus 1

Top IMPs

DOSTARLIMAB 13 BELANTAMAB MAFODOTIN 7 BELIMUMAB 6 DEPEMOKIMAB 5 DEXAMETHASONE 5 NIRAPARIB TOSILATE MONOHYDRATE 5 BEPIROVIRSEN 4 DEXAMETHASONE PH. EUR. 4 GSK5764227 4 PEMBROLIZUMAB 4 HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT 3 MEPOLIZUMAB 3

All trials — page 4

85 total

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function Ended

2023-509915-10-00 Phase I (Other) 1 country
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Phase III 7 countries DEPEMOKIMAB
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Phase III 12 countries BENRALIZUMAB; DEPEMOKIMAB; MEPOLIZUMAB
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outc… Ended

2024-510663-34-00 Phase II 2 countries ZANAMIVIR
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Phase III 14 countries NIRAPARIB TOSILATE MONOHYDRATE; PEMBROLIZUMAB
TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended

2023-505894-33-00 Phase II 6 countries CARBOPLATIN; CISPLATIN; DOSTARLIMAB; PEMBROLIZUMAB; PEMETREXED
A study of belimumab in children with systemic lupus erythematosus (SLE) Ended

2023-509413-37-00 Phase II 2 countries BELIMUMAB
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced S… Ended

2024-513574-21-00 Phase I 2 countries
Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome. Ended

2024-515247-28-00 Phase III 1 country MEPOLIZUMAB
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO) Ended

2024-512730-15-00 Phase II 1 country BELIMUMAB
A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue… Ended

2023-509027-41-00 Phase I (Other) 4 countries
A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants … Ended

2023-510340-20-00 Phase I (Other) 2 countries
A study to investigate the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of GSK4524101 alone or with nira… Ended

2024-520197-36-00 Phase I (FiH) 8 countries GSK4524101A; NIRAPARIB TOSILATE MONOHYDRATE

Showing 73–85 of 85 trials

← All sponsors A–Z